Le Lézard
Classified in: Health
Subject: TDS

Guerbet To Showcase Next Generation Digital Solutions at HIMSS20


PRINCETON, N.J., Feb. 26, 2020 /PRNewswire/ -- Guerbet, a global leader in medical imaging, will feature both established and next generation products from the company's digital portfolio at the 2020 HIMSS Global Health Conference & Exhibition in Orlando, FL.

(PRNewsfoto/Guerbet LLC USA)

At booth #4488, interactive workstations will provide live demonstrations of Guerbet's digital offerings, which include:

Contrast&Care® will be additionally featured in InterSystems booth #3301. Guerbet has partnered with InterSystems, a global leader in information technology platforms, to optimize the integration of Contrast&Care® into IT systems of hospitals and medical imaging centers worldwide.

A presentation on Contrast&Care® will take place on Tuesday, March 10 at 1:00 pm in the InterSystems booth about how InterSystems IRIS for Health facilitates the interoperability, data storage, and business intelligence of Guerbet solutions.

To learn how Guerbet is helping providers close the loop with smart connectivity, visit Guerbet at booth #4488, InterSystems booth #3301, or visit www.digitalsolutions.guerbet.us.  

About Guerbet
Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. A pioneer since more than 90 years in the field of contrast media with over 2,800 people globally, Guerbet is continuously innovating with 9% of revenue dedicated to Research & Development and four centers in France, Israel and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B ? mid caps) and generated ?817 million in revenue in 2019. For more information about Guerbet, please visit www.guerbet.com.

SOURCE Guerbet LLC USA


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: